Chronic myelogenous leukemia CD34+CD38- cells response to histone deacetylase inhibitor analog and imatinib mesylate
Summary:
Analysis of sorted chronic myelogenous leukemia (CML) CD34+CD38- cells cultured with histone deacetylase inhibitor analog LBH589 (LBH) and/or BCR-ABL tyrosine kinase inhibitor imatinib mesylate (IM). Results provide insight into molecular mechanisms underlying treatment of CML with LBH and IM.
GPL570:
[HG-U133_Plus_2] Affymetrix Human Genome U133 Plus 2.0 Array
Citation:
Zhang B, Strauss AC, Chu S, Li M et al. Effective targeting of quiescent chronic myelogenous leukemia stem cells by histone deacetylase inhibitors in combination with imatinib mesylate. Cancer Cell 2010 May 18;17(5):427-42. PMID: 20478526
